Ryan Handoko1, Phillip Chan2, Linda Jagodzinski3, Suteeraporn Pinyakorn2,3,4, Sasiwimol Ubolyam5, Nittaya Phanuphak2, Carlo Sacdalan2, Eugene Kroon2, Netsiri Dumrongpisutikul6, Robert Paul7, Victor Valcour8, Jintanat Ananworanich2,3,4,9, Sandhya Vasan2,3,4, Serena Spudich1. 1. Yale School of Medicine, New Haven, Connecticut, USA. 2. SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 3. United States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring. 4. The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA. 5. HIV-NAT, The Thai Red Cross AIDS Research Center. 6. Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 7. Missouri Institute of Mental Health, University of Missouri-St. Louis, St. Louis, Missouri. 8. Department of Neurology, University of California San Francisco Memory and Aging Center, Sandler Neurosciences Center, San Francisco, California, USA. 9. Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: Despite suppression of HIV-1 replication in the periphery by antiretroviral therapy (ART), up to 10% of treated individuals have quantifiable HIV-1 in the CSF, termed CSF escape. CSF escape may be asymptomatic but has also been linked to progressive neurological disease, and may indicate persistence of HIV in the central nervous system (CNS). CSF escape has not yet been assessed after initiation of ART during acute HIV-1 infection (AHI). DESIGN: Prospective cohort study. SETTING: Major voluntary counseling and testing site in Bangkok, Thailand. PARTICIPANTS: Participants identified and initiated on ART during AHI who received an optional study lumbar puncture at pre-ART baseline or after 24 or 96 weeks of ART. MAIN OUTCOME MEASURES: Paired levels of CSF and plasma HIV-1 RNA, with CSF greater than plasma HIV-1 RNA defined as CSF escape. RESULTS: Two hundred and four participants had paired blood and CSF sampling in at least one visit at baseline, week 24, or week 96. Twenty-nine participants had CSF sampling at all three visits. CSF escape was detected in 1/90 at week 24 (CSF HIV-1 RNA 2.50 log10 copies/ml, plasma HIV-1 RNA <50 copies/ml), and 0/55 at week 96. CONCLUSION: Although levels of CSF HIV-1 RNA in untreated AHI are high, initiating treatment during AHI results in a very low rate of CSF escape in the first 2 years of treatment. Early treatment may improve control of HIV-1 within the CNS compared with treatment during chronic infection, which may have implications for long-term neurological outcomes and CNS HIV-1 persistence.
OBJECTIVE: Despite suppression of HIV-1 replication in the periphery by antiretroviral therapy (ART), up to 10% of treated individuals have quantifiable HIV-1 in the CSF, termed CSF escape. CSF escape may be asymptomatic but has also been linked to progressive neurological disease, and may indicate persistence of HIV in the central nervous system (CNS). CSF escape has not yet been assessed after initiation of ART during acute HIV-1 infection (AHI). DESIGN: Prospective cohort study. SETTING: Major voluntary counseling and testing site in Bangkok, Thailand. PARTICIPANTS: Participants identified and initiated on ART during AHI who received an optional study lumbar puncture at pre-ART baseline or after 24 or 96 weeks of ART. MAIN OUTCOME MEASURES: Paired levels of CSF and plasma HIV-1 RNA, with CSF greater than plasma HIV-1 RNA defined as CSF escape. RESULTS: Two hundred and four participants had paired blood and CSF sampling in at least one visit at baseline, week 24, or week 96. Twenty-nine participants had CSF sampling at all three visits. CSF escape was detected in 1/90 at week 24 (CSF HIV-1 RNA 2.50 log10 copies/ml, plasma HIV-1 RNA <50 copies/ml), and 0/55 at week 96. CONCLUSION: Although levels of CSF HIV-1 RNA in untreated AHI are high, initiating treatment during AHI results in a very low rate of CSF escape in the first 2 years of treatment. Early treatment may improve control of HIV-1 within the CNS compared with treatment during chronic infection, which may have implications for long-term neurological outcomes and CNS HIV-1 persistence.
Authors: Sarah B Joseph; Laura P Kincer; Natalie M Bowman; Chris Evans; Michael J Vinikoor; Christopher K Lippincott; Magnus Gisslén; Serena Spudich; Prema Menezes; Kevin Robertson; Nancie Archin; Angela Kashuba; Joseph J Eron; Richard W Price; Ronald Swanstrom Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Alan Winston; Andrea Antinori; Paola Cinque; Howard S Fox; Magnus Gisslen; Timothy J Henrich; Scott Letendre; Deborah Persaud; Richard W Price; Serena Spudich Journal: AIDS Date: 2019-12-01 Impact factor: 4.177
Authors: Michael J Peluso; Francesca Ferretti; Julia Peterson; Evelyn Lee; Dietmar Fuchs; Antonio Boschini; Magnus Gisslén; Nancy Angoff; Richard W Price; Paola Cinque; Serena Spudich Journal: AIDS Date: 2012-09-10 Impact factor: 4.177
Authors: Susanna L Lamers; Rebecca Rose; Lishomwa C Ndhlovu; David J Nolan; Marco Salemi; Ekaterina Maidji; Cheryl A Stoddart; Michael S McGrath Journal: J Neurovirol Date: 2015-11-16 Impact factor: 2.643
Authors: Shelli F Farhadian; Hetal Mistry; Tobias Kirchwey; Jennifer Chiarella; Rachela Calvi; Michelle Chintanaphol; Payal Patel; Marie L Landry; Kevin Robertson; Serena S Spudich Journal: Open Forum Infect Dis Date: 2019-12-14 Impact factor: 3.835
Authors: Nametso Kelentse; Sikhulile Moyo; Kesaobaka Molebatsi; Olorato Morerinyane; Shatho Bitsang; Ontlametse T Bareng; Kwana Lechiile; Tshepo B Leeme; David S Lawrence; Ishmael Kasvosve; Rosemary Musonda; Mosepele Mosepele; Thomas S Harrison; Joseph N Jarvis; Simani Gaseitsiwe Journal: Biomedicines Date: 2022-06-13